MedDataX Logo

Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles

NCT ID: NCT01191710

Last Updated: 2010-09-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to explore whether the incidence of progesterone rise in the late follicular phase differs between GnRH-agonist and GnRH-antagonist protocols for IVF and whether this has an impact on the probability of pregnancy achievement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In view of the current debate concerning possible differences in efficacy between the two GnRH analogues, the current study aimed to explore whether progesterone control in the late follicular phase differs when GnRH-agonist is used as compared to GnRH-antagonist and if so to what extend does the progesterone rise have an impact on the probability of achieving a pregnancy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Outcome After In Vitro Fertilization (IVF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Antagonist group

Antagonist protocol for IVF

Group Type EXPERIMENTAL

In vitro fertilization

Intervention Type OTHER

In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation

Agonist group

Long Agonist protocol for IVF

Group Type ACTIVE_COMPARATOR

In vitro fertilization

Intervention Type OTHER

In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

In vitro fertilization

In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

IVF pregnancy embryo-transfer progesterone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age \< 39
* follicle-stimulating hormone (FSH) \< 12
* gonadotropin dose 100-300IU

Exclusion Criteria

* endometriosis
* known endocrine disorder
* blood analyzed in another laboratory
Minimum Eligible Age

21 Years

Maximum Eligible Age

39 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioGenesis

INDUSTRY

Sponsor Role collaborator

Universitair Ziekenhuis Brussel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Human Reproduction and Genetics Foundation (HRG)

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Basil Tarlatzis, MD

Role: STUDY_CHAIR

BioGenesis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Biogenesis

Thessaloniki, Pylaia, Greece

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Greece

References

Explore related publications, articles, or registry entries linked to this study.

Papanikolaou EG, Kolibianakis EM, Pozzobon C, Tank P, Tournaye H, Bourgain C, Van Steirteghem A, Devroey P. Progesterone rise on the day of human chorionic gonadotropin administration impairs pregnancy outcome in day 3 single-embryo transfer, while has no effect on day 5 single blastocyst transfer. Fertil Steril. 2009 Mar;91(3):949-52. doi: 10.1016/j.fertnstert.2006.12.064. Epub 2007 Jun 6.

Reference Type BACKGROUND
PMID: 17555751 (View on PubMed)

Papanikolaou EG, Pados G, Grimbizis G, Bili E, Kyriazi L, Polyzos NP, Humaidan P, Tournaye H, Tarlatzis B. GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Hum Reprod. 2012 Jun;27(6):1822-8. doi: 10.1093/humrep/des066. Epub 2012 Mar 14.

Reference Type DERIVED
PMID: 22422777 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.hrg.gr

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ProgRise001

Identifier Type: -

Identifier Source: org_study_id